Skip to content
Medical Health Aged Care

Tribute to FIP President, the late Dominique Jordan

Pharmaceutical Society of Australia (PSA) < 1 mins read

20 August 2023

The Pharmaceutical Society of Australia (PSA) is today paying tribute to International Pharmaceutical Federation (FIP) President Mr Dominique Jordan, who sadly passed away overnight.

A Swiss community pharmacist, Dominique became a member of FIP 20 years ago. In his home country, his actions to advance pharmacy included roles as president and CEO, concurrently, of pharmaSuisse, the Swiss association of pharmacists.

Dominique was elected president of FIP in 2018. Before that, he served FIP and global pharmacy as chair of the Board of Pharmaceutical Practice (2014-2018). 

PSA National President Dr Fei Sim FPS paid tribute to Mr Jordan.

“Despite his ongoing battle with cancer, Dominique always captured the tenacity and positivity in life,” Dr Sim said.

“Dominique has worked tirelessly and given much of his life to professional pharmacy both in Australia and internationally and leaves a huge legacy to the profession. He will be greatly missed.

“On behalf of Australian pharmacists, PSA offers our deepest condolences to Mr Jordan’s friends, family, and colleagues.”

As per FIP Statutes (article 16.13), president-elect Paul Sinclair AM MPS will begin his term effective immediately.

 

Media contact:   Georgia Clarke   M: 0480 099 798      E: georgia.clarke@psa.org.au

The Pharmaceutical Society of Australia is the only national peak body that represents all of Australia’s 36,000 pharmacists across all practice settings. We want every Australian to have access to the best healthcare, and this must include optimising access to pharmacists’ knowledge and medicines expertise at the forefront of our healthcare system.

Follow us on socials:      Facebook     Twitter      LinkedIn     Instagram

More from this category

  • Medical Health Aged Care
  • 29/05/2024
  • 17:07
JJP Biologics

JJP Biologics Announces Positive Decision to Execute a First-in-Human Clinical Trial of Anti-Inflammatory mAb JJP-1212 (anti-CD89)

JJP Biologics has received a positive conclusion on the Clinical Trial Application assessment for a Phase I Study of a potential first-in-class anti-CD89 antagonist,…

  • Contains:
  • Medical Health Aged Care
  • 29/05/2024
  • 11:54
NDARC

Long-term prescription opioid use after hospital declining: study

UNSW Sydney medical researchers have shed light on post-hospital prescription opioid use. A large, linked data study has detailed the scale of prescription opioid…

  • Contains:
  • Medical Health Aged Care
  • 29/05/2024
  • 11:45
Cleo Diagnostics Limited ASX.COV

Cleo’s Ovarian Cancer Blood Test Outperforms Current Clinical Benchmark

Highlights A benchmarking study comparing CLEO’s ovarian cancer blood test against ultrasound has been published in scientific journal “Cancers” The study confirmed that CLEO’s initial test for the surgical triage market:– Significantly outperforms current clinical workflows that use CA125 and ultrasound to predict malignancy;– Correctly detected 90% of early-stage cancers compared to only 50% using standard workflows; and– Can be easily adopted for use into clinical practice. The superior performance of CLEO’s test now compared to all current routine clinical tools shows the significant global potential for the test in clinical decision making prior to surgical intervention. MELBOURNE, AUSTRALIA, 29…

Media Outreach made fast, easy, simple.

Feature your press release on Medianet's News Hub every time you distribute with Medianet. Pay per release or save with a subscription.